RS20050692A - Azabiciklični derivati piridilometila i benzizoksazola - Google Patents

Azabiciklični derivati piridilometila i benzizoksazola

Info

Publication number
RS20050692A
RS20050692A YUP-2005/0692A YUP20050692A RS20050692A RS 20050692 A RS20050692 A RS 20050692A YU P20050692 A YUP20050692 A YU P20050692A RS 20050692 A RS20050692 A RS 20050692A
Authority
RS
Serbia
Prior art keywords
octahydro
pyridin
pyrido
isoxazol
ylmethyl
Prior art date
Application number
YUP-2005/0692A
Other languages
English (en)
Serbian (sr)
Inventor
Gene Michael Bright
Michael Aaron Brodney
Bishop Wlodecki
Original Assignee
Pfizer Production Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Production Inc., filed Critical Pfizer Production Inc.,
Publication of RS20050692A publication Critical patent/RS20050692A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
YUP-2005/0692A 2003-03-12 2004-02-23 Azabiciklični derivati piridilometila i benzizoksazola RS20050692A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45392503P 2003-03-12 2003-03-12
PCT/IB2004/000499 WO2004081007A1 (en) 2003-03-12 2004-02-23 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives

Publications (1)

Publication Number Publication Date
RS20050692A true RS20050692A (sr) 2007-11-15

Family

ID=32990837

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0692A RS20050692A (sr) 2003-03-12 2004-02-23 Azabiciklični derivati piridilometila i benzizoksazola

Country Status (30)

Country Link
US (1) US7345038B2 (enExample)
EP (1) EP1608648B1 (enExample)
JP (2) JP3910627B2 (enExample)
KR (2) KR100767854B1 (enExample)
CN (1) CN100389115C (enExample)
AP (1) AP2005003390A0 (enExample)
AR (1) AR043537A1 (enExample)
AU (2) AU2004220327B2 (enExample)
BR (1) BRPI0408248A (enExample)
CA (1) CA2518740C (enExample)
EA (1) EA009527B1 (enExample)
EC (1) ECSP056011A (enExample)
GT (1) GT200400041A (enExample)
HR (1) HRP20050798A2 (enExample)
IL (1) IL170290A (enExample)
MA (1) MA27747A1 (enExample)
MX (1) MXPA05009660A (enExample)
NL (1) NL1025710C2 (enExample)
NO (1) NO20054095L (enExample)
OA (1) OA13038A (enExample)
PA (1) PA8597501A1 (enExample)
PE (1) PE20041057A1 (enExample)
PL (1) PL378749A1 (enExample)
RS (1) RS20050692A (enExample)
TN (1) TNSN05224A1 (enExample)
TW (1) TW200502234A (enExample)
UA (1) UA78437C2 (enExample)
UY (1) UY28225A1 (enExample)
WO (1) WO2004081007A1 (enExample)
ZA (1) ZA200506373B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
WO2005082370A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
HRP20090495T1 (hr) * 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
JP2008512441A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
CN102405214A (zh) 2009-04-20 2012-04-04 Osi药物有限责任公司 C-吡嗪-甲胺的制备
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9980945B2 (en) 2015-01-13 2018-05-29 Vanderbilt University Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2023083445A1 (en) 2021-11-10 2023-05-19 Symrise Ag Compositions comprising trpm8 agonistic cooling agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
US5167034A (en) * 1990-06-18 1992-11-24 International Business Machines Corporation Data integrity for compaction devices
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
CA2118936A1 (en) 1991-09-25 1993-04-01 Gene M. Bright Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
ATE185565T1 (de) 1992-06-16 1999-10-15 Pfizer Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica
US5731307A (en) 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
CA2289574C (en) 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
SK2612001A3 (en) 1998-08-26 2001-11-06 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
HK1039326A1 (zh) 1998-09-18 2002-04-19 Abbott Gmbh & Co. Kg 4氨基吡咯并嘧啶作为激酶抑制剂
HK1039325B (en) 1998-09-18 2006-02-24 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
HUP0202248A3 (en) 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders

Also Published As

Publication number Publication date
EP1608648A1 (en) 2005-12-28
AU2004220327B2 (en) 2010-06-24
HRP20050798A2 (en) 2006-02-28
ZA200506373B (en) 2006-10-25
CA2518740A1 (en) 2004-09-23
MA27747A1 (fr) 2006-02-01
NL1025710C2 (nl) 2005-10-10
IL170290A (en) 2011-02-28
OA13038A (en) 2006-11-10
JP3910627B2 (ja) 2007-04-25
HK1085725A1 (zh) 2006-09-01
AU2004220327A1 (en) 2004-09-23
KR100767854B1 (ko) 2007-10-17
UY28225A1 (es) 2004-11-08
JP2006519830A (ja) 2006-08-31
GT200400041A (es) 2005-03-23
AP2005003390A0 (en) 2005-09-30
UA78437C2 (en) 2007-03-15
CN100389115C (zh) 2008-05-21
KR20070074667A (ko) 2007-07-12
AU2010203303A1 (en) 2010-08-12
NO20054095L (no) 2005-09-26
CN1759116A (zh) 2006-04-12
BRPI0408248A (pt) 2006-03-01
KR20050113221A (ko) 2005-12-01
PA8597501A1 (es) 2005-05-24
TW200502234A (en) 2005-01-16
ECSP056011A (es) 2006-01-27
EA200501148A1 (ru) 2006-04-28
CA2518740C (en) 2011-01-11
TNSN05224A1 (fr) 2007-06-11
NL1025710A1 (nl) 2004-09-14
PL378749A1 (pl) 2006-05-15
PE20041057A1 (es) 2005-01-22
US7345038B2 (en) 2008-03-18
WO2004081007A1 (en) 2004-09-23
JP2007051155A (ja) 2007-03-01
US20050026922A1 (en) 2005-02-03
NO20054095D0 (no) 2005-09-02
MXPA05009660A (es) 2005-10-20
AR043537A1 (es) 2005-08-03
EP1608648B1 (en) 2012-07-18
EA009527B1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
AU2010203303A1 (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
US9714232B2 (en) Substituted piperazine compounds and methods of use thereof
US20040152724A1 (en) Azabicyclic compounds are central nervous system active agents
KR20170095919A (ko) 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도
TW200829243A (en) Azaadamantane derivatives and methods of use
US20190135799A1 (en) Heterocyclic compound
EP3039024A1 (en) Pyrrolopyridine or pyrazolopyridine derivatives
JP2011140509A (ja) インダゾール、ベンゾチアゾール、及びベンゾイソチアゾール、並びにそれらの調製及び使用
KR20180110132A (ko) 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
CN104163813B (zh) 取代的吲哚化合物及其使用方法和用途
CA3120971A1 (en) Substituted furanopyrimidine compounds as pde1 inhibitors
KR20180004817A (ko) 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
WO2015169180A1 (en) Substituted piperazine compounds and methods and use thereof
TW201120048A (en) Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
KR20190097258A (ko) Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
HK1085725B (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
JP2025526300A (ja) エモパミル結合タンパク質阻害剤及びその使用